lenalidomide

P1/2, N=60, Active, not recruiting, PETHEMA Foundation | Recruiting --> Active, not recruiting

P2, N=30, Active, not recruiting, PETHEMA Foundation | Trial primary completion date: Mar 2025 --> Mar 2026

This study investigated the associations of sFLC κ, λ and the κ/λ ratio with clinical features, cytogenetic abnormalities, prognosis and response to the VRd regimen (bortezomib, lenalidomide, dexamethasone) in newly diagnosed MM (NDMM) patients, aiming to optimize risk stratification. In conclusion, abnormal sFLC κ is a potential marker of poor prognosis and suboptimal response to VRd therapy in NDMM. Integrating sFLC κ with the R-ISS improves risk stratification, providing new evidence for clinical application of this biomarker.

Notably, L5 showed superior potency in MCF-7 cells with IC50; 1.16 µM compared to the FDA-approved thiosemicarbazone Triapine with IC50; 4.27 µM, while displaying minimal toxicity toward non-tumorigenic MCF-10a breast epithelial cells with selectivity index > 86.20, consistent with ADMET predictions. Molecular docking and molecular dynamics simulations demonstrated stronger binding affinity and greater complex stability of L5 with PTOV1 compared to the FDA approved drug Lenalidomide, supporting L5 drug likeness and therapeutic potential...L5 enhanced H2AX phosphorylation, suppressed PARP and BCL-XL levels, and increased active caspase-3 driving L5 induced apoptosis. This study identifies L5 as a potent anticancer agent in breast cancer, acting through modulation of the PTOV1-AKT-β-catenin signaling axis, and highlights PTOV1 as a promising therapeutic target.

P2/3, N=660, Recruiting, AbbVie

P2, N=10, Completed, Ciusss de L'Est de l'Île de Montréal | Active, not recruiting --> Completed

P1, N=39, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027

P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting

P1/2, N=208, Active, not recruiting, GlaxoSmithKline | Phase classification: P2 --> P1/2

P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

P2, N=29, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting

P4, N=141, Terminated, Takeda | Trial completion date: Nov 2026 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Mar 2026; All participants on the study have concluded treatment, core study activities are complete, and the scientific goals of the study have been met.